Experimental Bleomycin Lung in Mice. A Contribution to the Pathogenesis of Pulmonary Fibrosis
Overview
Authors
Affiliations
Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF).
Aribindi K, Liu G, Albertson T Expert Rev Clin Pharmacol. 2024; 17(9):817-835.
PMID: 39192604 PMC: 11441789. DOI: 10.1080/17512433.2024.2396121.
Lung surfactant as a biophysical assay for inhalation toxicology.
Liu J, Sayes C Curr Res Toxicol. 2023; 4:100101.
PMID: 36687216 PMC: 9849875. DOI: 10.1016/j.crtox.2022.100101.
Andersson-Sjoland A, Karlsson J, Rydell-Tormanen K Lab Invest. 2015; 96(2):206-17.
PMID: 26367492 DOI: 10.1038/labinvest.2015.100.
Comprehensive lung injury pathology induced by mTOR inhibitors.
Aparicio G, Calvo M, Medina V, Fernandez O, Jimenez P, Lema M Clin Transl Oncol. 2009; 11(8):499-510.
PMID: 19661024 DOI: 10.1007/s12094-009-0394-y.
Extracellular superoxide dismutase in pulmonary fibrosis.
Gao F, Kinnula V, Myllarniemi M, Oury T Antioxid Redox Signal. 2007; 10(2):343-54.
PMID: 17999630 PMC: 2290736. DOI: 10.1089/ars.2007.1908.